Hantavirus: Lethality, Transmission and What GPs Need to Know
Hantavirus carries case fatality rates up to 40% in some syndromes. Here is what clinicians and the public genuinely need to worry about.
Dupilumab in Severe Asthma: Real-World Cohort Data Begin to Arrive
Three new studies examine dupilumab and biologic therapy in severe type 2 asthma, adding real-world weight to existing trial evidence.
Parkinson's Neuroprotection 2025: Three Strategies Under Review
Stem cell therapy, System Xc- pathway modulation, and Ayurvedic add-on regimens are each being evaluated as neuroprotective strategies in Parkinson's disease.
Perilla Oil Nanoemulsion Improves Psoriasis Scores in Mouse Model
A perilla essential oil nanoemulsion reduced erythema, scaling, and inflammatory markers in imiquimod-induced psoriasis, with curcumin co-loading enhancing skin permeation.
Addiction Recovery: A Canadian Perspective on a Global Crisis
The Canadian Academy for Addiction Psychiatry (CAAP) highlights the urgent need for enhanced mental health and <a href="https://thelifesciencefeed.com/keywords/addiction-treatment">addiction treatment</a> services, especially in the wake of the COVID-19 pandemic. Their commentary provides a framework that other countries might consider, although questions of scalability remain.
What Still Eludes Us in MASH Research?
MASH (metabolic dysfunction-associated steatohepatitis) is a complex disease, and while we've made strides, key mechanistic details remain elusive. This demands a sharper focus on translational studies that can directly inform clinical practice.
SGLT2 Inhibitors and Ferroptosis: A New Mechanistic Picture in HF
Emerging evidence links SGLT2 inhibitors' cardiac benefit to ferroptosis suppression, offering a potential mechanistic explanation for their efficacy in heart failure.
JAK Inhibitors in RA: 2025 EULAR Safety Update Redraws Risk Guidance
The 2025 EULAR RA update revises JAK inhibitor safety guidance, with implications for prescribing in higher-risk patients.
SGLT2 Inhibitors and Ferroptosis: A New Mechanistic Picture in HF
Emerging evidence links SGLT2 inhibitors' cardiac benefit to ferroptosis suppression, offering a potential mechanistic explanation for their efficacy in heart failure.
2025 AHA/ACC Hypertension Guidelines: What GPs Need Now
The 2025 AHA/ACC hypertension guidelines update prescribing priorities. Here is what the evidence says about antihypertensive management today.
PCSK9 Inhibitors Move Upstream: Evolocumab Tested in Diabetes Without Known Atherosclerosis
VESALIUS-CV tests evolocumab in diabetic patients without established atherosclerosis, while new trials probe plaque biology and lipid pathways beyond LDL.
SGLT2 Inhibitors Post-Heart Transplant: What the Data Show
3 min readAtrial Fibrillation and Cardio-Kidney-Metabolic Risk: A Systemic Challenge
2 min readAtrial Fibrillation Complexity: How Reliable is Registry Data?
3 min readTAVI and Aortic Dissection Risk: Is Valve Type a Factor?
3 min readSSEPs to Monitor Cerebral Perfusion During TCAR TAVR Procedures
2 min readWhat Still Eludes Us in MASH Research?
MASH (metabolic dysfunction-associated steatohepatitis) is a complex disease, and while we've made strides, key mechanistic details remain elusive. This demands a sharper focus on translational studies that can directly inform clinical practice.
Lorlatinib and New-Onset Diabetes Practical Monitoring for Oncologists
Patients on lorlatinib require vigilant monitoring for hyperglycemia and ketoacidosis, regardless of pre-existing diabetes risk factors. Proactive screening and early intervention are crucial to mitigate potential severe complications and ensure patient safety.
Lorlatinib and the Enigma of Autoantibody-Negative Diabetes
Patients on lorlatinib may develop diabetes with unusual characteristics, including the absence of typical autoantibodies. This presents a diagnostic challenge, requiring clinicians to consider drug-induced etiologies even when initial immunological markers are negative.
Unraveling MASH: Implications for Clinical Practice
2 min readSGLT2 Inhibitors: Promise and Peril in Prader-Willi Syndrome?
4 min readOpportunistic Osteoporosis Screening from CT Scans A Validated Approach?
4 min readMetformin, Liraglutide, and Gut Microbiome Shifts in Youth-Onset T2D
4 min readCan Routine CT Scans Predict Osteoporosis Risk?
3 min readSGLT2 Inhibitors in Prader-Willi Syndrome: Weighing Renal Risks and Glycemic Control
2 min read